Remove FDA Remove Food and Drug Administration Remove Physicians Remove Transportation
article thumbnail

Lexicon gets FDA approval for Inpefa to treat heart failure

Pharmaceutical Technology

Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat heart failure. Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1).

article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS).

article thumbnail

MedWand Solutions Receives FDA 510k Clearance

Legacy MEDSearch

Food and Drug Administration (FDA) has granted 510(k) clearance to the MedWand,” shared MedWand CEO and Co-Founder, Robert Rose. “As MedWand Mobile Clinic – Designed for physician or home visits and remote patient monitoring applications. To request a demo today visit www.medwand.com. “I

FDA 52
article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The US Food and Drug Administration (FDA) recently announced new draft guidance for life science companies on increasing diversity and inclusion in clinical trials to improve enrollments of underrepresented racial and ethnic populations. FDA Commissioner Robert M.

FDA 52
article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The US Food and Drug Administration (FDA) recently announced new draft guidance for life science companies on increasing diversity and inclusion in clinical trials to improve enrollments of underrepresented racial and ethnic populations. FDA Commissioner Robert M.

FDA 52
article thumbnail

Untapped opportunity: the growing potential of clinical trials in Georgia

Pharmaceutical Technology

Another factor driving Georgia’s growth in the clinical trial space is the recent significant investment in the country’s health system, creating several new facilities and programmes, as well as increasing the number of experienced physicians.